Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Argenx Se ( (ARGX) ) has provided an announcement.
On March 19, 2026, Argenx SE filed its 2025 Annual Report, including audited consolidated financial statements for the year ended December 31, 2025, with the Dutch Authority for the Financial Markets. The filing, presented under IFRS and in U.S. dollars, formalizes the company’s 2025 financial reporting and will be submitted for shareholder adoption at the 2026 General Meeting.
The same day, Argenx furnished a Form 6-K to the U.S. Securities and Exchange Commission to incorporate the Dutch annual report by reference into several existing Form S-8 registration statements. This step streamlines compliance for its U.S.-listed securities and employee share plans, reinforcing Argenx’s dual listing and regulatory alignment between European and U.S. markets.
The most recent analyst rating on (ARGX) stock is a Buy with a $1000.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.
Spark’s Take on ARGX Stock
According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.
Score is driven primarily by strong financial performance (rapid 2025 growth, high margins, and a very conservative balance sheet) and a constructive earnings-call outlook with meaningful label-expansion catalysts. Offsetting factors are weak near-term technical momentum and a premium valuation with no dividend support, plus execution risks from low reported gross margin and rising OpEx.
To see Spark’s full report on ARGX stock, click here.
More about Argenx Se
Argenx SE is a Netherlands-based biotechnology company focused on developing and commercializing antibody-based therapies for autoimmune diseases. Its lead product, VYVGART (including subcutaneous formulations such as VYVGART HYTRULO and VYVDURA), is approved across multiple major markets for generalized myasthenia gravis and other immune-mediated conditions, positioning the group as a global rare-disease immunology player.
Average Trading Volume: 359,412
Technical Sentiment Signal: Buy
Current Market Cap: $42.59B
For a thorough assessment of ARGX stock, go to TipRanks’ Stock Analysis page.